Skip to content

Trial Summary

A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy



ACTRN/NCT /ethics:


Scientific title:

A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)

Sponsor / Cooperative group:

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Trial & Patient Characteristics

Cancer TypeKidney
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
Tumour Stream Non-clear Cell Renal Cell Carcinoma
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2019-04-11
Anticipated End Date2024-04-30

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2204
Principal InvestigatorDr Francis Parnis
Recruitment StatusRecruiting
HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlison Richards
Phone08 8206 4835
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting